124 related articles for article (PubMed ID: 37272688)
1. LaSOM 335, active against bladder cancer cells, interferes with Let-60 (hRas) and reduces CD73 expression/activity.
Kagami LP; Gonçalves IL; da Silva ÁC; Silva AC; das Neves GM; Göethel G; Spillere A; Dos Santos MR; Figueiró F; Garcia SC; Ávila DS; Battastini AMO; Eifler-Lima VL
Chem Biol Drug Des; 2023 Sep; 102(3):536-546. PubMed ID: 37272688
[TBL] [Abstract][Full Text] [Related]
2. Ecto-5'-nucleotidase/CD73 contributes to the radiosensitivity of T24 human bladder cancer cell line.
Dietrich F; Figueiró F; Filippi-Chiela EC; Cappellari AR; Rockenbach L; Tremblay A; de Paula PB; Roesler R; Filho AB; Sévigny J; Morrone FB; Battastini AMO
J Cancer Res Clin Oncol; 2018 Mar; 144(3):469-482. PubMed ID: 29305710
[TBL] [Abstract][Full Text] [Related]
3. A monastrol-derived compound, LaSOM 63, inhibits ecto-5'nucleotidase/CD73 activity and induces apoptotic cell death of glioma cell lines.
Figueiró F; Mendes FB; Corbelini PF; Janarelli F; Jandrey EH; Russowsky D; Eifler-Lima VL; Battastini AM
Anticancer Res; 2014 Apr; 34(4):1837-42. PubMed ID: 24692717
[TBL] [Abstract][Full Text] [Related]
4. Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody-Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function.
Jin R; Liu L; Xing Y; Meng T; Ma L; Pei J; Cong Y; Zhang X; Ren Z; Wang X; Shen J; Yu K
Mol Cancer Ther; 2020 Nov; 19(11):2340-2352. PubMed ID: 32943546
[TBL] [Abstract][Full Text] [Related]
5. Alterations in the extracellular catabolism of nucleotides are involved in the antiproliferative effect of quercetin in human bladder cancer T24 cells.
Rockenbach L; Bavaresco L; Fernandes Farias P; Cappellari AR; Barrios CH; Bueno Morrone F; Oliveira Battastini AM
Urol Oncol; 2013 Oct; 31(7):1204-11. PubMed ID: 22137869
[TBL] [Abstract][Full Text] [Related]
6. CD73 Is Regulated by the EGFR-ERK Signaling Pathway in Non-small Cell Lung Cancer.
Griesing S; Liao BC; Yang JC
Anticancer Res; 2021 Mar; 41(3):1231-1242. PubMed ID: 33788714
[TBL] [Abstract][Full Text] [Related]
7. CD73/NT5E is a target of miR-30a-5p and plays an important role in the pathogenesis of non-small cell lung cancer.
Zhu J; Zeng Y; Li W; Qin H; Lei Z; Shen D; Gu D; Huang JA; Liu Z
Mol Cancer; 2017 Feb; 16(1):34. PubMed ID: 28158983
[TBL] [Abstract][Full Text] [Related]
8. CD73 promotes proliferation and migration of human cervical cancer cells independent of its enzyme activity.
Gao ZW; Wang HP; Lin F; Wang X; Long M; Zhang HZ; Dong K
BMC Cancer; 2017 Feb; 17(1):135. PubMed ID: 28202050
[TBL] [Abstract][Full Text] [Related]
9. NTPDase3 and ecto-5'-nucleotidase/CD73 are differentially expressed during mouse bladder cancer progression.
Rockenbach L; Braganhol E; Dietrich F; Figueiró F; Pugliese M; Edelweiss MI; Morrone FB; Sévigny J; Battastini AM
Purinergic Signal; 2014 Sep; 10(3):421-30. PubMed ID: 24464643
[TBL] [Abstract][Full Text] [Related]
10. Identification and Expression Analysis of CD73 Inhibitors in Cervical Cancer.
Iqbal J; Basharat A; Bano S; Abid SMA; Pelletier J; Sévigny J
Med Chem; 2021; 17(8):866-874. PubMed ID: 32981507
[TBL] [Abstract][Full Text] [Related]
11. IFN-alpha induced adenosine production on the endothelium: a mechanism mediated by CD73 (ecto-5'-nucleotidase) up-regulation.
Niemelä J; Henttinen T; Yegutkin GG; Airas L; Kujari AM; Rajala P; Jalkanen S
J Immunol; 2004 Feb; 172(3):1646-53. PubMed ID: 14734746
[TBL] [Abstract][Full Text] [Related]
12. The distinct role of CD73 in the progression of pancreatic cancer.
Zhou L; Jia S; Chen Y; Wang W; Wu Z; Yu W; Zhang M; Ding G; Cao L
J Mol Med (Berl); 2019 Jun; 97(6):803-815. PubMed ID: 30927045
[TBL] [Abstract][Full Text] [Related]
13. CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer.
Wettstein MS; Buser L; Hermanns T; Roudnicky F; Eberli D; Baumeister P; Sulser T; Wild P; Poyet C
Dis Markers; 2015; 2015():785461. PubMed ID: 26543299
[TBL] [Abstract][Full Text] [Related]
14. CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis.
Ma XL; Shen MN; Hu B; Wang BL; Yang WJ; Lv LH; Wang H; Zhou Y; Jin AL; Sun YF; Zhang CY; Qiu SJ; Pan BS; Zhou J; Fan J; Yang XR; Guo W
J Hematol Oncol; 2019 Apr; 12(1):37. PubMed ID: 30971294
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Ecto-5'-nucleotidase (CD73) promotes T-47D human breast cancer cells invasion and adhesion to extracellular matrix.
Zhou P; Zhi X; Zhou T; Chen S; Li X; Wang L; Yin L; Shao Z; Ou Z
Cancer Biol Ther; 2007 Mar; 6(3):426-31. PubMed ID: 17471030
[TBL] [Abstract][Full Text] [Related]
16. Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer.
Zhi X; Wang Y; Yu J; Yu J; Zhang L; Yin L; Zhou P
IUBMB Life; 2012 Nov; 64(11):911-20. PubMed ID: 23086814
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of CD73 Confers Acquired Radioresistance and is Required for Maintaining Irradiation-selected Pancreatic Cancer Cells in a Mesenchymal State.
Nguyen AM; Zhou J; Sicairos B; Sonney S; Du Y
Mol Cell Proteomics; 2020 Feb; 19(2):375-389. PubMed ID: 31879272
[TBL] [Abstract][Full Text] [Related]
18. The volatile anesthetic isoflurane increases endothelial adenosine generation via microparticle ecto-5'-nucleotidase (CD73) release.
Kim M; Ham A; Kim KY; Brown KM; Lee HT
PLoS One; 2014; 9(6):e99950. PubMed ID: 24945528
[TBL] [Abstract][Full Text] [Related]
19. Characterization of ectonucleotidases in human medulloblastoma cell lines: ecto-5'NT/CD73 in metastasis as potential prognostic factor.
Cappellari AR; Rockenbach L; Dietrich F; Clarimundo V; Glaser T; Braganhol E; Abujamra AL; Roesler R; Ulrich H; Battastini AM
PLoS One; 2012; 7(10):e47468. PubMed ID: 23094051
[TBL] [Abstract][Full Text] [Related]
20. CD73 is associated with poor prognosis in high-grade serous ovarian cancer.
Turcotte M; Spring K; Pommey S; Chouinard G; Cousineau I; George J; Chen GM; Gendoo DM; Haibe-Kains B; Karn T; Rahimi K; Le Page C; Provencher D; Mes-Masson AM; Stagg J
Cancer Res; 2015 Nov; 75(21):4494-503. PubMed ID: 26363007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
